Vemurafenib (PLX4032, RG7204)

製品コードS1267 別名:RO5185426

Vemurafenib (PLX4032, RG7204)化学構造

分子量(MW):489.92

Vemurafenib (PLX4032, RG7204)は一種の新たで、有効なB-RafV600E阻害剤で、無細胞試験でIC50値が31nMです。

サイズ 価格 在庫  
USD 114 あり
USD 88 あり
USD 340 あり
USD 970 あり

文献中の引用(70)

カスタマーフィードバック(16)

  • The regressing tumour microenvironment stimulates the outgrowth, infiltration and metastasis of drug-resistant clones. b, Bioluminescent signal of drug-resistant A375RTGL cells in vemurafenib-sensitive, A375 tumours, treated with vehicle or vemurafenib for 5 days (vehicle, n = 36; vemurafenib, n = 15 tumours). D, day. c, EdU incorporation in A375R-TGL cells in A375/A375R-TGL tumours treated with vehicle or vemurafenib for 4 days, as determined by FACS (vehicle, n = 8; vemurafenib, n = 6 tumours). d, Bioluminescent signal of A375R-TGL tumours alone, treated with vehicle or vemurafenib for 5 days (vehicle, n 5 38; vemurafenib, n = 15 tumours). e, Bioluminescent signal of TGLexpressing drug-resistant cancer cells (A375R, M249R4, PC9 and H2030) in drug-sensitive tumours (Colo800, LOX, UACC62, M249, H3122 and HCC827) treated with vehicle or drugs (vemurafenib, crizotinib and erlotinib) for 5 days (n (from left to right on the graph) = 6, 7, 12, 12, 9, 9, 25, 26, 9, 12, 12, 12, 16 and 11 tumours). f, Spontaneous lung metastasis by A375R cells in mice bearing A375/A375R-TGL tumours treated with vehicle or vemurafenib (10 days), visualized by BLI (n = 4).

    Nature 2015 520(7547), 368-72. Vemurafenib (PLX4032, RG7204) purchased from Selleck.

    FRA1 downregulation during RAFi treatment drives the reactive secretome. c, Relative mRNA levels of FRA1 during vemurafenib exposure [0.1-1 uM]. d, Representative immunofluorescence staining of A375/A375R tumours for GFP (A375R, green) and FRA1 (red) after vehicle or vemurafenib treatment (5 days). DAPI, 49,6-diamidino-2-phenylindole. Scale bars, 50 um.

    Nature 2015 520(7547), 368-72. Vemurafenib (PLX4032, RG7204) purchased from Selleck.

  • Acquired EGFR expression in BRAF(V600E) mutant melanoma after vemurafenib resistance. Immunohistochemical (IHC) analysis (ultraView DAB stain, brown) showing increased EGFR expression in formalin-fixed paraffin embedded (FFPE) (Patient number 1-5) and frozen (Patient number 6) melanoma tissue sections from BRAF(V600E) mutant melanoma patients who developed resistance to vemurafenib, dabrafenib or trametinib as indicated. For each patient, the first biopsy is from the pre-treatment tumour; the second biopsy was performed after the tumour had progressed under treatment. For patient number 4, the first biopsy was performed when the patient was in partial response, but rapidly developed secondary resistance. Then 4.5 months later, the second biopsy was taken.

    Nature 2014 508(7494), 118-22. Vemurafenib (PLX4032, RG7204) purchased from Selleck.

    Long-term colony formation assay of thyroid cancer (8505C), CRC (OXCO-1, COLO741 and WiDr) and melanoma (A375) cells. Cells were grown in the absence or presence of PLX4032 at the indicated concentrations for 10-14 days. For each cell line, all dishes were fixed at the same time, stained and photographed.

    Nature 2012 483(7387):100-3. Vemurafenib (PLX4032, RG7204) purchased from Selleck.

  • Resistance to BRAF(V600E) inhibition in WiDr cells is mediated through feedback activation of EGFR. Biochemical responses of WiDr cells treated with PLX4032, cetuximab or gefitinib, or their combinations, were documented by western blot analysis. Cells were harvested at 6 h after drug treatment. BRAF(V600E) inhibition results in strong upregulation of Tyr1068 p-EGFR and Ser473 phosphorylated-AKT (p-AKT), which is abrogated by EGFR inhibitors. Furthermore, combination treatments result in complete inhibition of phosphorylated MEK (p-MEK) and phosphorylated ERK (p-ERK). Heat shock protein 90 (HSP90) served as a control.

    Nature 2012 483(7387):100-3. Vemurafenib (PLX4032, RG7204) purchased from Selleck.

    Nature, 2016, 537(7620):422-426.. Vemurafenib (PLX4032, RG7204) purchased from Selleck.

  • Science, 2014, 346(6205):1255784.. Vemurafenib (PLX4032, RG7204) purchased from Selleck.

    Impact of BRAF and SYK/MEK inhibition on ERK activation in primary CLL cells. Representative Western blot analysis for pERK and tERK of the protein lysate at the indicated concentrations of vemurafenib and dabrafenib for patients 1 and 2. The experiment was performed 2 times with similar results.

    J Clin Invest 2014 124(11), 5074-84. Vemurafenib (PLX4032, RG7204) purchased from Selleck.

  • The B-Raf inhibitor PLX4032 decreases cell surface DR5 levels . BCPAP cells were treated with the indicated concentrations of PLX4032 for 12 h and then harvested for extraction of cellular total RNA and subsequent RT-PCR to detection of DR5.

    Oncogene 2015 10.1038/onc.2015.97. Vemurafenib (PLX4032, RG7204) purchased from Selleck.

    Stat3 is activated in melanoma cells with acquired resistance to vemurafenib. Sensitive and resistant A375 melanoma cells were stimulated by different doses of vemurafenib as indicated. Total protein was collected 6 hours after stimulation. Protein expressions of phospho–ERK1/2, Stat3, phospho-Stat3, and paired box homeotic gene 3 (PAX3) were analyzed by western blot along with tubulin, which served as a loading control.

    J Invest Dermatol 2013 133, 2041. Vemurafenib (PLX4032, RG7204) purchased from Selleck.

  • Clonogenic assays of VM21 (b) and VM1 (c) cells treated with 1 μM PD166866 (PD) and 0.1 μM RG7204 (RG) for 14 days. For VM21 cells, the combination index (CI) value indicating synergism is shown. For VM1 cells, inefficacy of 1 μM PD166866 alone precluded calculation of a CI value and P-values for reduction of clonal growth are shown instead. a, P<0.05 versus RG; b, P<0.01 versus PD.

    J Invest Dermatol 2011 131, 2087-95. Vemurafenib (PLX4032, RG7204) purchased from Selleck.

    BRAF inhibition improves autologous tumor recognition by CD8+ tumor-infiltrating lymphocytes. (A and B) Tumor-infiltrating lymphocytes (TILs) were co-cultured with autologous BRAFV600E mutant melanoma target cell lines treated with vemurafenib (Vem) at low or high dose, or left untreated. (A) Frequency of tumor necrosis factor α (TNF α)-and interferon γ (IFN γ)-producing CD8+ TILs. (B) Frequency of CD8+ TILs producing TNF α and IFN γ and simultaneously mobilizing CD107a upon co-culture with autologous tumor cells. *p < 0.05; ** p < 0.01; ***p < 0.001.

    Oncoimmunology 2012 1, 1476-1483. Vemurafenib (PLX4032, RG7204) purchased from Selleck.

  • Fig 1 represents the cell cytotoxicity assay to study the effect of Vemurafenib on ABCC10 (MRP7) overexpressing cells. Table 1 shows the data suggesting reversal of resistance ABCC10 overexpressing cells with Vemurafenib at 20 μM using Paclitaxel as a substrate. HEK293 is a human embryonic kidney cell line while HEK293/MRP7 is an MRP7 overexpressing cell line generated by MRP7 gene transfection. Cepharanthine is a positive control. Vemurafenib (20 μM) in combination with Paclitaxel can reverse MDR mediated by MRP7 over-expressing cells as it decreased the resistance fold from 24-fold to 1-fold.

    Dr. Zhe-Sheng Chen of St. John's University. Vemurafenib (PLX4032, RG7204) purchased from Selleck.

    Fig 2 represents the cell cytotoxicity assay to study the effect of vemurafenib on ABCG2 (BCRP) overexpressing cells. Table 2 shows the data suggesting reversal of resistance ABCG2 overexpressing cells with vemurafenib at 20 μM using mitoxantrone as a substrate. H460 is a hepatic carcinoma cell line while H460/MX20 is an ABCG2 overexpressing cell line made resistant by drug selection with mitoxantrone. FTC (Fumitremorgin C) is a positive control. Vemurafenib (20 μM) in combination with Mitoxantrone can reverse MDR mediated by ABCG2 over-expressing cells as it decreased the resistance fold from 133-fold to 93-fold.

    Dr. Zhe-Sheng Chen of St. John's University. Vemurafenib (PLX4032, RG7204) purchased from Selleck.

  • represents the effect of Vemurafenib on the accumulation of [3H]-Mitoxantrone. Vemurafenib increased the intra-cellular accumulation of Mitoxantrone in ABCG2 overexpressing H460/MX20 cells compared with parental H460 cells. From the figure, the accumulation in H460/MX20 control is decreased whereas in presence of Vemurafenib 20 μM, it is significantly increases the [3H]-Mitoxantrone accumulation.

    Dr. Zhe-Sheng Chen of St. John's University. Vemurafenib (PLX4032, RG7204) purchased from Selleck.

     

    Anti-ErbB3 mAbs differently counteract the increase of ErbB3-dependent AKT phosphorylation and potentiate growth inhibition induced by vemurafenib. LOX IMVI melanoma cells serum starved and treated with vemurafenib (0.3μ M) for 24 h were incubated or not with 20 μ g/ml of anti-ErbB3 mAbs A4 (a),A3orA2(d). Western blot analysis shows that A4 and A3, but not A2 mAbs abrogate receptor phosphorylation and ATK signaling. For densitometric analysis pErbB3/ErbB3, pERK/ERK and pAKT/ATK values are expressed as fold change with respect to the control unstimulated cells to which value = 1 was assigned. Results are expressed as mean values from three independent experiments. LOX IMVI cells were grown in the presence of different doses of vemurafenib alone or in combination with 20 μg/ml of A4 (b),A3 or A2(e) mAbs for 10 days. Cells were then fixed and stained with crystal violet(c). Cells were then dissolved in a Methanol/SDS solution and the adsorbance (595 nm) was read using a microplate ELISA reader (b, e). Quantitative analysis for curve fitting and for IC50 evaluation, performed by KaleidaGraph software, shows that the treatment with A4 and A3 but not with A2 enhances the inhibitory effect of vemurafenib on cell growth (IC50 vem = 155 nM; IC50 vem + A4 = 36 nM; IC50 vem + A3 = 62, IC50 vem + A2 = 146 nM). Results are reported as mean values±standard deviation (SD) from three independent experiments. p-values were calculated using Student ’s t test and significance level has been defined as p < 0,05. For IC50 vem + A4 and IC50 vem + A3 p < 0,001 vs IC50 vem; IC50 vem + A2 NS vs IC50 vem.

    Vemurafenib (PLX4032, RG7204) purchased from Selleck.

製品安全説明書

Raf阻害剤の選択性比較

生物活性

製品説明 Vemurafenib (PLX4032, RG7204)は一種の新たで、有効なB-RafV600E阻害剤で、無細胞試験でIC50値が31nMです。
特性 A novel and potent inhibitor of the B-RAFV600E oncoprotein.
ターゲット
SRMS [1]
(Cell-free assay)
ACK1 [1]
(Cell-free assay)
B-Raf (V600E) [1]
(Cell-free assay)
C-Raf [1]
(Cell-free assay)
MAP4K5 (KHS1) [1]
(Cell-free assay)
18 nM 19 nM 31 nM 48 nM 51 nM
体外試験

PLX4032 inhibits B-RAFV600E, C-RAF, as well as wildtype B-RAF, with IC50 of 31 nM, 48 nM and 100 nM, respectively. PLX4032 also inhibits several non-RAF kinases, including ACK1, KHS1, and SRMS, with IC50 of 18 nM to 51 nM. [1] In melanoma cell lines, the inhibitory effect by PLX4032 depends on B-RAF mutational status, because PLX4032 potently inhibits those harboring B-RAF V600 mutants, including V600E, V600D, V600K, and V600R, but not wildtype or other mutants. The IC50 values of PLX4032 on these cells, including MALME-3M, Colo829, Colo38, A375, SK-MEL28, and A2058, ranges from 20 nM to 1 μM. In these cells, PLX4032 (0.1 μM to 30 μM) also inhibits the phosphorylation of both MEK1/2 and ERK1/2. [2] PLX4032 is highly effective in the treatment of melanoma, for its ability of inhibiting B-RAFV600E. However, PLX4032 displays limited effect in colon cancer patients that also carrying B-RAFV600E oncoprotein. The reason for this is that, in colon cancer cells, B-RAFV600E inhibition by PLX4032 results in a rapid feedback EGFR activation, which compensates for the PLX4032-inhibited cell proliferation. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A375 MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6xNFAh|ryP NV22VVdiQTZiaB?= M175NmROW09? MVvJR|UxRTR5IH7N M{HiU|E5PDV6MEWz
ARO M17UVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLiNVAxKM7:TR?= NFXLUpU6PiCq Mn64SG1UVw>? MkPKTWM2OD1{MEWgcm0> NXK0eWpyOTh2NUiwOVM>
NPA NGjOZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\KeoUyODBizszN MV:5OkBp NH3ueWtFVVOR M2XmNWlEPTB;Mk[gcm0> NIr3RZgyQDR3OEC1Ny=>
TPCI M3THd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFezWYYyODBizszN NIfuNVY6PiCq NX\VeXlJTE2VTx?= NEfpSHZKSzVyPUGwMlc4KM7:TR?= NFSwZVcyQDR3OEC1Ny=>
A375 MY\BdI9xfG:|aYOgRZN{[Xl? MkjONVAh|ryP NV71U4w1TE2VTx?= MXrQdo9ud3SnczDhdI9xfG:2aXOg[IVifGh? MlK4NVg1PThyNUO=
ARO MXLGeY5kfGmxbjDBd5NigQ>? NHO2VG8yOCEQvF2= MWm3NkBp M4rGTGROW09? M{PFc2lv\HWlZYOgeIhmKHKnZYjwdoV{e2mxbjDv[kB1cGViTlnTJJB2dXB? MV:xPFQ2QDB3Mx?=
8505C (BRAF V600E/V600E) NFT5R|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjSRVN[QTZiaB?= NIDwbGZKSzVyPUW3JI5OKA>? NVnHdIQ6OjBzNEmxN|Y>
SW1736 (BRAF WT/V600E) M{nOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;UZZNtQTZiaB?= NYT0bItjUUN3ME2yPUBvVQ>? NVjaZnFIOjBzNEmxN|Y>
BHT101 (BRAF WT/V600E) MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTHXG1yQTZiaB?= Mm[0TWM2OD17NzDuUS=> NX3NbYJkOjBzNEmxN|Y>
BCPAP (BRAF WT/V600E) MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUe5OkBp MlLyTWM2OD15ODDuUS=> Mk\3NlAyPDlzM{[=
C643 (HRAS G13R)≥ 500 Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWq5OkBp M2faUmlEPTBi4polJFUxOCCwTR?= M1PqPFIxOTR7MUO2
HTH7 (NRAS Q61R) NET5UXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjEVJA6PiCq NYXJ[285UUN3MPMJqUAyODByIH7N Mm\YNlAyPDlzM{[=
CAL62 (KRAS G12R) > 1000 > 1000 Mn7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUO5OkBp NFHV[ZZKSzVyPjCxNFAxKG6P MWiyNFE1QTF|Nh?=
TPC-1 (RET/PTC1) NFfKWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTKPVYhcA>? MYPJR|Ux6onnMUCwNEBvVQ>? MVeyNFE1QTF|Nh?=
PC NFzhcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T4[Fk3KGh? MYXJR|UxRiBzMECwJI5O MUmyNFE1QTF|Nh?=
Calu-6 M4LoNWZ2dmO2aX;uJGF{e2G7 MYmx5qCK|ryP MVGxJIg> M3;qU2ROW09? NWG3c4V5SWO2aY\heIV{KE2HSz;FVmshcW5iY3XscJMhf2m2aDD3bYxlNXS7cHWgRnJCTg>? MXuyNFE4QTdyNR?=
C4 M4rS[mZ2dmO2aX;uJGF{e2G7 M{frfFMh|ryP NFXCWYM1QCCq MWLEUXNQ MVrJcoNz\WG|ZYOgZ49tdGGpZX6gd5lvfGinc3nzJIFv\CCmZXPy[YF{\XNiSVytPEBmgHC{ZYPzbY9v MnzRNlU6QDl3ME[=
VMM12 M4LEeGZ2dmO2aX;uJGF{e2G7 NV3oU5B2OyEQvF2= NIXYWJk1QCCq MmLkSG1UVw>? MVnJcoNz\WG|ZYOgZ49tdGGpZX6gd5lvfGinc3nzJIFv\CCmZXPy[YF{\XNiSVytPUBmgHC{ZYPzbY9v M{\HTlI2QTh7NUC2
SKMEL19 MlzTSpVv[3Srb36gRZN{[Xl? NWKxXFBDPiEQvF2= M4raV|Q5KGh? NG\PV3NFVVOR MVPUdolo\2W{czDFVkB{fHKnc4O= MYiyN|M3OjJ2MB?=
UKF-NB-3 (ABCB1) MV;GeY5kfGmxbjDBd5NigQ>? NEP6bIIyNjJ3INM1US=> M165WlIhcA>? MmW5SG1UVw>? MYXFcohidmOnczDhZ4N2dXWuYYTpc44hd2ZidHjlJIZtfW:{ZYPj[Y51KEGEQ1KxJJN2[nO2cnH0[UBzcG:mYX3pcoUhOTJ| MnroNlQ4OzV5Nk[=
UKF-NB-3 NILnOFZHfW6ldHnvckBCe3OjeR?= NYP6TmM{OS5{NTFCuW0> MmrJNkBp M1y3eGROW09? MYrTbYdvcW[rY3HueIx6KGGoZnXjeJMhd25iYXPjeY12dGG2aX;uJI9nKHSqZTDmcJVwemW|Y3XueEBCSkOEMTDzeYJ{fHKjdHWgdohw\GGvaX7lJFEzOw>? NEfJbZUzPDd|NUe2Oi=>
A375 (BRAFV600E) NFvISI5HfW6ldHnvckBCe3OjeR?= MUK4JIg> NHq2THRFVVOR Mmj4TY5kemWjc3XzJIlvfHKjY3XscJVt[XJiUl;TJIFv\CCQTzDs[ZZmdHNi MkKzNlU{PjN4NES=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In B-RAFV600E-mutant mice xenograft models, PLX4032 (6 mg/kg–20 mg/kg) inhibits tumor growth. [1] In mice xenograft models of LOX, Colo829, and A375 cells, PLX4032 (12.5 mg/kg–100 mg/kg) inhibits tumor growth and prolongs mice survival. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

RAF kinase activity measurements:

The kinase activities of wild-type RAF and mutants are determined by measuring phosphorylation of biotinylated-BAD protein. For each enzyme (0.01 ng), 20 μL reactions are carried out in 20 mM Hepes (pH 7.0), 10 mM MgCl2, 1 mM DTT, 0.01% (v/v) Tween-20, 50 nM biotin-BAD protein, and 1 mM ATP at room temperature. Reactions are stopped at 5 min with 5 μL of a solution containing 20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, 0.3% (w/v) bovine serum albumin (BSA). The stop solution also includes phospho-BAD (Ser112) antibody, streptavidin-coated donor beads, and protein A acceptor beads. The antibody and beads are pre-incubated in stop solution in the dark at room temperature for 30 min. The final dilution of antibody is 1/2000 and the final concentration of each bead is 10 μg/mL. The assay plates are incubated at room temperature for one hour and then are read on a PerkinElmer AlphaQuest reader. Mutant activities are the average of two different batches of purified protein assayed in duplicate in three different experiments.
細胞試験:

[2]

+ 展開
  • 細胞株: MALME-3M, Colo829, Colo38, A375, SK-MEL28, and A2058 cells
  • 濃度: 0–10 μM , dissolved in DMSO
  • 反応時間: 5 days
  • 実験の流れ:

    Cellular proliferation is evaluated by MTT assay. Briefly, cells are plated in 96-well microtiter plates at a density of 1000 to 5000 cells per well in a volume of 180 μL. PLX4032 is prepared at 10 times the final assay concentration in media containing 1% DMSO. Twenty-four hours after cell plating, 20 μL of the appropriate dilution of PLX4032 are added to plates in duplicate. The plates are assayed for proliferation 6 days after the cells are plated. Percent inhibition is calculated and the IC50 is determined from the regression of a plot of the logarithm of the concentration versus percent inhibition.


    (参考用のみ)
動物試験:

[2]

+ 展開
  • 動物モデル: Mice (athymic nude) xenograft models of LOX, Colo829, and A375 cells
  • 製剤: Formulated as microprecipitated bulk powder (MBP), suspended at the desired concentration in an aqueous vehicle containing 2% Klucel LF, and adjusted to pH 4 with dilute HCl
  • 投薬量: 12.5 mg/kg–100 mg/kg
  • 投与方法: Oral gavage twice daily
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 97 mg/mL (197.99 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
体内 順序で溶剤を入れること:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 489.92
化学式

C23H18ClF2N3O3S

CAS No. 918504-65-1
保管
in solvent
別名 RO5185426

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01585415 Terminated Metastatic Cancer|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 9, 2012 Phase 1
NCT01843738 Not yet recruiting BRAFV600 Mutation|Stage IV Melanoma University of Utah January 2017 Phase 1
NCT02314481 Not yet recruiting Non-small Cell Lung Cancer University College, London|Hoffmann-La Roche January 2017 Phase 2
NCT03013491 Recruiting Solid Tumor|Lymphoma CytomX Therapeutics January 2017 Phase 1|Phase 2
NCT02908672 Recruiting Melanoma Hoffmann-La Roche January 2017 Phase 3
NCT03005639 Recruiting Stage IIIB-C Melanoma Inova Health Care Services|Genentech, Inc. December 2016 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    How about the half-life of Vemurafenib(S1267)?

  • 回答:

    It was reported that the half-life of the compound is 57 hours.

  • 問題2:

    The vemurafenib power, when prepared in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O solutions, form a pellet down the tube?

  • 回答:

    When prepare this kind of vehicle, please dissolve the drug in DMSO clearly first. If it dissolves not readily, please sonicate and warm in the water bath at about 45 degree. Then add PEG and Tween. After they mixed homogeneously, then dilute with water.

Raf信号経路図

Raf Inhibitors with Unique Features

相関Raf製品

Tags: Vemurafenib (PLX4032, RG7204)を買う | Vemurafenib (PLX4032, RG7204) ic50 | Vemurafenib (PLX4032, RG7204)供給者 | Vemurafenib (PLX4032, RG7204)を購入する | Vemurafenib (PLX4032, RG7204)費用 | Vemurafenib (PLX4032, RG7204)生産者 | オーダーVemurafenib (PLX4032, RG7204) | Vemurafenib (PLX4032, RG7204)化学構造 | Vemurafenib (PLX4032, RG7204)分子量 | Vemurafenib (PLX4032, RG7204)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID